Relationship between serum and saliva theophylline levels in patients with cystic fibrosis

James Blanchard, Suzanne Suzanne, Wayne J Morgan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Theophylline levels in stimulated and unstimulated mixed saliva were compared with total and free (unbound) serum theophylline levels in 11 outpatients with cystic fibrosis (CF) who were using theophylline regularly. Stimulated saliva from CF patients predicted both total and unbound serum theophylline concentrations to within ±1 μ g/ml in 53.3 and 80.0%, respectively, of the samples examined. In addition, the total serum levels from CF patients could be used to predict unbound serum concentrations to within ± 1 μ g/ml in 100% of the cases examined. Furthermore, it was observed that prediction equations derived in a previous study with asthmatics employing identical methodology would allow both unbound and total serum theophylline levels to be predicted from saliva levels in CF patients with a degree of accuracy and precision that was approximately equal to or slightly better than the results obtained using prediction equations derived in other CF patients. These results indicate that saliva levels allow predictions of the unbound serum theophylline levels with greater accuracy and precision than they predict total serum theophylline levels. In addition, total serum levels can be used to reliably predict unbound serum levels. The use of mixed stimulated saliva is recommended as a reliable noninvasive method for monitoring unbound serum theophylline levels. The therapeutic range for saliva, which corresponds to the accepted total serum concentration range of 10–20 μg/ml, is ∼5.55–11.3 μg/ml.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalTherapeutic Drug Monitoring
Volume14
Issue number1
StatePublished - 1992

Fingerprint

Theophylline
Saliva
Cystic Fibrosis
Serum
Outpatients
Monitoring

Keywords

  • Cystic fibrosis
  • Saliva
  • Serum
  • Theophylline

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Relationship between serum and saliva theophylline levels in patients with cystic fibrosis. / Blanchard, James; Suzanne, Suzanne; Morgan, Wayne J.

In: Therapeutic Drug Monitoring, Vol. 14, No. 1, 1992, p. 48-54.

Research output: Contribution to journalArticle

@article{b5d470939d024e45815bc2e77cb922a3,
title = "Relationship between serum and saliva theophylline levels in patients with cystic fibrosis",
abstract = "Theophylline levels in stimulated and unstimulated mixed saliva were compared with total and free (unbound) serum theophylline levels in 11 outpatients with cystic fibrosis (CF) who were using theophylline regularly. Stimulated saliva from CF patients predicted both total and unbound serum theophylline concentrations to within ±1 μ g/ml in 53.3 and 80.0{\%}, respectively, of the samples examined. In addition, the total serum levels from CF patients could be used to predict unbound serum concentrations to within ± 1 μ g/ml in 100{\%} of the cases examined. Furthermore, it was observed that prediction equations derived in a previous study with asthmatics employing identical methodology would allow both unbound and total serum theophylline levels to be predicted from saliva levels in CF patients with a degree of accuracy and precision that was approximately equal to or slightly better than the results obtained using prediction equations derived in other CF patients. These results indicate that saliva levels allow predictions of the unbound serum theophylline levels with greater accuracy and precision than they predict total serum theophylline levels. In addition, total serum levels can be used to reliably predict unbound serum levels. The use of mixed stimulated saliva is recommended as a reliable noninvasive method for monitoring unbound serum theophylline levels. The therapeutic range for saliva, which corresponds to the accepted total serum concentration range of 10–20 μg/ml, is ∼5.55–11.3 μg/ml.",
keywords = "Cystic fibrosis, Saliva, Serum, Theophylline",
author = "James Blanchard and Suzanne Suzanne and Morgan, {Wayne J}",
year = "1992",
language = "English (US)",
volume = "14",
pages = "48--54",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Relationship between serum and saliva theophylline levels in patients with cystic fibrosis

AU - Blanchard, James

AU - Suzanne, Suzanne

AU - Morgan, Wayne J

PY - 1992

Y1 - 1992

N2 - Theophylline levels in stimulated and unstimulated mixed saliva were compared with total and free (unbound) serum theophylline levels in 11 outpatients with cystic fibrosis (CF) who were using theophylline regularly. Stimulated saliva from CF patients predicted both total and unbound serum theophylline concentrations to within ±1 μ g/ml in 53.3 and 80.0%, respectively, of the samples examined. In addition, the total serum levels from CF patients could be used to predict unbound serum concentrations to within ± 1 μ g/ml in 100% of the cases examined. Furthermore, it was observed that prediction equations derived in a previous study with asthmatics employing identical methodology would allow both unbound and total serum theophylline levels to be predicted from saliva levels in CF patients with a degree of accuracy and precision that was approximately equal to or slightly better than the results obtained using prediction equations derived in other CF patients. These results indicate that saliva levels allow predictions of the unbound serum theophylline levels with greater accuracy and precision than they predict total serum theophylline levels. In addition, total serum levels can be used to reliably predict unbound serum levels. The use of mixed stimulated saliva is recommended as a reliable noninvasive method for monitoring unbound serum theophylline levels. The therapeutic range for saliva, which corresponds to the accepted total serum concentration range of 10–20 μg/ml, is ∼5.55–11.3 μg/ml.

AB - Theophylline levels in stimulated and unstimulated mixed saliva were compared with total and free (unbound) serum theophylline levels in 11 outpatients with cystic fibrosis (CF) who were using theophylline regularly. Stimulated saliva from CF patients predicted both total and unbound serum theophylline concentrations to within ±1 μ g/ml in 53.3 and 80.0%, respectively, of the samples examined. In addition, the total serum levels from CF patients could be used to predict unbound serum concentrations to within ± 1 μ g/ml in 100% of the cases examined. Furthermore, it was observed that prediction equations derived in a previous study with asthmatics employing identical methodology would allow both unbound and total serum theophylline levels to be predicted from saliva levels in CF patients with a degree of accuracy and precision that was approximately equal to or slightly better than the results obtained using prediction equations derived in other CF patients. These results indicate that saliva levels allow predictions of the unbound serum theophylline levels with greater accuracy and precision than they predict total serum theophylline levels. In addition, total serum levels can be used to reliably predict unbound serum levels. The use of mixed stimulated saliva is recommended as a reliable noninvasive method for monitoring unbound serum theophylline levels. The therapeutic range for saliva, which corresponds to the accepted total serum concentration range of 10–20 μg/ml, is ∼5.55–11.3 μg/ml.

KW - Cystic fibrosis

KW - Saliva

KW - Serum

KW - Theophylline

UR - http://www.scopus.com/inward/record.url?scp=0026585591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026585591&partnerID=8YFLogxK

M3 - Article

C2 - 1546389

AN - SCOPUS:0026585591

VL - 14

SP - 48

EP - 54

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -